| Followers | 9 |
| Posts | 1278 |
| Boards Moderated | 1 |
| Alias Born | 09/09/2000 |
Thursday, August 01, 2002 2:57:26 PM
Hello pontang
Glad to have you aboard with us.
The web looks great things are falling into place more and more everyday.
I agree now we need Vince to come on with the plans so we can get this baby back to where it should be.
Wise
Wise Investments
http://www.wise-investments.net
Glad to have you aboard with us.
The web looks great things are falling into place more and more everyday.
I agree now we need Vince to come on with the plans so we can get this baby back to where it should be.
Wise
Wise Investments
http://www.wise-investments.net
Wise
Recent JANX News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/28/2026 09:02:08 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/28/2026 08:56:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/28/2026 08:22:13 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/28/2026 08:15:41 PM
- Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development • Business Wire • 04/27/2026 08:01:00 PM
- Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014 • Business Wire • 04/16/2026 08:01:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/13/2026 08:05:35 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 04/02/2026 08:02:23 PM
- Janux secures $35 million milestone payment from Bristol Myers Squibb • IH Market News • 04/01/2026 02:01:33 PM
- Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment • Business Wire • 04/01/2026 12:01:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/26/2026 09:47:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 09:10:46 PM
- Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights • Business Wire • 02/26/2026 09:01:00 PM
- Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011 • Business Wire • 02/17/2026 12:00:00 PM
- Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors • Edgar (US Regulatory) • 02/06/2026 09:23:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:01:40 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 02/05/2026 01:00:24 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/26/2026 09:20:12 PM
- Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer • Business Wire • 01/26/2026 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 01/23/2026 09:08:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2026 09:30:59 PM
- Janux Therapeutics jumps on new collaboration with Bristol Myers Squibb • IH Market News • 01/22/2026 01:39:50 PM
- Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors • Business Wire • 01/22/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2026 02:00:15 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/03/2026 02:00:12 AM
